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Abstract
Background: Because of the lack of suitable in vivo models of giant cell tumor of bone (GCT), little is known about
its underlying fundamental pro-tumoral events, such as tumor growth, invasion, angiogenesis and metastasis. There
is no existing cell line that contains all the cell and tissue tumor components of GCT and thus in vitro testing of
anti-tumor agents on GCT is not possible. In this study we have characterized a new method of growing a GCT
tumor on a chick chorio-allantoic membrane (CAM) for this purpose.
Methods: Fresh tumor tissue was obtained from 10 patients and homogenized. The suspension was grafted onto
the CAM at day 10 of development. The growth process was monitored by daily observation and photo
documentation using in vivo biomicroscopy. After 6 days, samples were fixed and further analyzed using standard
histology (hematoxylin and eosin stains), Ki67 staining and fluorescence in situ hybridization (FISH).
Results: The suspension of all 10 patients formed solid tumors when grafted on the CAM. In vivo microscopy and
standard histology revealed a rich vascularization of the tumors. The tumors were composed of the typical
components of GCT, including (CD51+/CD68+) multinucleated giant cells whichwere generally less numerous and
contained fewer nuclei than in the original tumors. Ki67 staining revealed a very low proliferation rate. The FISH
demonstrated that the tumors were composed of human cells interspersed with chick-derived capillaries.
Conclusions: A reliable protocol for grafting of human GCT onto the chick chorio-allantoic membrane is
established. This is the first in vivo model for giant cell tumors of bone which opens new perspectives to study this
disease and to test new therapeutical agents.
Background
Giant cell tumor of bone (GCT) is an aggressive skeletal
lesion typically located in the epiphyseal end of a long
bone [1-3]. The tumor predominantly occurs in the
third and fourth decade of life with a slight predilection
for females [3-8].
GCT is characterized by locally aggressive growth
usually leading to extensive bone destruction [9]. The
biological behavior of the tumor is, however unpredict-
able, and attempts to histologically grade the tumors
have failed [10-12]. At the genomic level however recur-
rent cases are characterized by random individual cell
aneusomy, while malignant cases show abnormalities at
array CGH level [13].
GCT is characterized by the presence of numerous
Cathepsin-K producing, CD33 +, CD14 - multinucleated
osteoclast-like giant cells and plump spindle-shaped
stromal cells that represent the main proliferating cell
population [14-17]. The spindle-shaped mononuclear
cells are believed to represent the neoplastic population
and are characterized at the cytogenetic level by telo-
meric associations and a peculiar telomere-protecting
capping mechanism [18]. Areas of regressive change
such as necrosis or fibrosis as well as extensive hemor-
rhage are frequently present.
The treatment of choice is intralesional curettage and
bone cement packing leading to a local recurrence rate
of 10 to 40% [1,19,20]; treatment options are limited
and recurrence rates are higher when GCT arises at a
surgical inaccessible location (e.g. spine and sacrum). In
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undergo sarcomatous transformation. In about 2% of
cases, patients develop lung metastases, which are
thought to represent benign pulmonary implants that
arise following vascular invasion [21-25].
The underlying pathobiology of GCT growth and
development of these complications is unknown. There
is no successful adjuvant treatment option, although
there are reports of a limited effect on tumor growth
following treatment with bisphosphonates [26,27] and
anti-RANKL antibodies [28], agents that inhibit the for-
mation and activity of the osteoclastic giant cells in the
tumor.
Thus far, attempts to grow GCT in animal models as
well as to derive suitable cell lines from primary tumors
have failed. This has limited the study of pathobiology
of GCT and the development of specific anti-GCT
agents. To address this problem we have examined
whether it is possible to establish the growth of GCT
short-term in vivo in a chick chorio-allantoic membrane
(CAM) assay.
The CAM is characterized by an extremely dense vas-
cular network with large vessels situated within the
somatic mesoderm and capillaries located within or
directly under the splanchnic mesoderm. This double-
layer membrane develops by fusion of the chorion with
the allantoic vesicle on embryonic day 4 - 5 [29]. Until
hatching the CAM physiologically absorbs calcium from
the shell, stores waste products and serves as a respira-
tory organ [30].
The CAM assay has been utilized as a model system
for more than a century to demonstrate development of
embryonic blood vessels, and to provide a host for the
grafting of bacteria, viruses and embryonic tissue. In the
last 25 years, the CAM assay has become established as
a model for angiogenesis research; this has been used to
provide highly reproducible models for aggressive and
malignant tumors including glioblastoma and pancreatic
adenocarcinoma [31,32].
The use of the CAM assay in bone tumor research has
only been sporadically reported. We recently published
the successful establishment of human osteosarcoma
cell lines on a CAM assay and provided evidence that
the MNNG-HOS cell line reproduces the key features of
human osteosarcoma growth when grafted on the CAM
[33]. This relatively simple experimental approach
enables tumor growth and vascularization to be easily
studied and permits the growth of tumors to be studied
in an inexpensive way.
In this report, we present the results of successful
establishment of human GCT in a CAM assay with
emphasis on the morphological characteristics of the
grafted tumors.
Methods
Patients
The patients included in this study had typical, histolo-
gically confirmed cases of giant cell tumors of bone
( G C T ) .T h em e a na g eo ft h ef i v em a l ea n df i v ef e m a l e
patients was 29.8 years; eight of ten were localized in
the extremities, one in the spine and one in the pelvis.
Four were recurrent cases (see Additional file 1). All
patients gave their written consent prior to tumor tissue
isolation for research studies. All samples were handled
in a coded fashion and the experiments were performed
according to the local ethical guidelines.
Giant cell suspension
Cell suspensions isolated from GCT tissue of 10 patients
were used in the experiment. Tissue samples were
minced and incubated at 37°C in RPMI with 5-10 ml
DNAse (2200 KU/100 ml - Sigma-Aldrich, Germany;
cat. no. DN-25-10MG) and 5-10 ml collagenase Type 2
(500 U/ml - PAA; Austria; cat. no. K21-240) for 3-8
hours. DNAse and collagenase solutions were mixed in
equal parts. The homogenized tissue solution was cen-
trifuged at 1200 rpm for 5 min and the cell pellet was
subsequently washed twice with RPMI 1640 (PAA Aus-
tria; cat. no. E15-840) supplemented with 10% Foetal
Bovine Serum FBS Gold (PAA Austria; cat. no. A15-
649) and 1% penicilline/streptomycine (PAA Austria;
cat. no. P11-010). This procedure was repeated four
times.
Freezing giant cell suspension
After the last washing step, the cell pellet was re-sus-
pended in CryoMaxx S freezing medium (PAA, Austria
cat. no. J05-013 - approximately 50 μlt o2 0 0μl cells
per ml freezing medium). One ml suspension was frozen
per cryotube (Nunc; Germany; cat. no. 368632). Finished
vials were frozen overnight at -70°C in a freezing con-
tainer (NALGENE
® Labware, Hereford, United Kingdom
Cat. No. 5100-0001) and stored in liquid nitrogen.
Thawing giant cell suspension
Cell culture medium RPMI 1640 (PAA Austria; cat. no.
E15-840) supplemented with 10% Foetal Bovine Serum
FBS Gold (PAA Austria; cat. no. A15-649) and 1% peni-
cilline/streptomycine (PAA Austria; cat. no. P11-010)
was preheated at 37°C and 50 ml were propounded in a
conical centrifuge tube. The frozen vial of giant cells
was thawed in a 37°C water bath to that point that it
was possible to decant the cells into the RPMI (a rest of
ice in the tube is necessary). The cells were decanted
into the RPMI medium and centrifuged at 1200 rpm for
5 min. The resultant cell pellet was subsequently washed
with RPMI 1640 four times. The yield of isolated cells
Balke et al. BMC Cancer 2011, 11:241
http://www.biomedcentral.com/1471-2407/11/241
Page 2 of 8was re-suspended and seeded on the day 10 CAM (20 μl
each).
The chick chorio-allantoic membrane assay
Fertilized white leghorn chicken eggs (Valo-SPF eggs,
Lohmann Tierzucht GmbH, Cuxhaven, Germany) were
incubated at a humidity of 70% and 37°C. At embryonic
day 3, 2 - 3 ml of albumen were removed with a syringe,
thus allowing detachment of the embryo and a small
window was cut into the eggshell. After verification of
normal development of the embryo the window was
sealed with tape. After 10 days of incubation small plas-
tic rings made out of Thermanox™ cover discs were
placed on the CAM. After gentle laceration of the CAM
surface 20 μl of re-suspended tumor suspension were
deposited into the rings. For the controls only 20 μlo f
RPMI was used.
Until day 16 CAMs were examined and photographed
in ovo with a digital camera (Olympus E330) attached to
a stereomicroscope. All embryos that died before day 16
were excluded from further analyses. Tumor volumes
were estimated by the following formula: V = 4/3*p*r
3 (r
= 1/2 * square root of diameter 1 * diameter 2) [31].
For further information of the technique of the CAM
assay see instructional videos in the ‘additional files’ sec-
tion (Additional files 2, 3, 4, 5, 6 and 7).
Histology and Immunohistochemistry
At embryonic day 16, (6 days of tumor growth), tumors
were fixed in vivo using 4% paraformaldehyde for 20
min. Tumors were removed and transferred into culture
dishes and samples were observed and photographed.
Relevant samples were embedded in paraffin and cut
into 10 μm sections. Tissue sections were stained with
hematoxylin-eosin and by immunohistochemistry using
an indirect immunoperoxidase technique, with mouse
monoclonal antibodies MIB-1, and KPI (both obtained
from DAKO-UK) and NCL-CD14 and NCL-CD51
(Novocastra, UK) directed against the proliferation mar-
ker Ki67, the macrophage/osteoclast marker CD68, the
monocyte/macrophage marker CD14, and the osteoclast
marker CD51 (vitronectin receptor) respectively. Results
were analyzed by standard light microscopy (Leica
DM2500 with Leica EC3 camera).
Interphase fluorescence in situ hybridization (FISH)
for the positive identification of cells with human origin
we performed an interphase FISH using human haploid
repeat sequence containing probe sets [34]. These
alpha-satellite probes specifically recognize (peri)centro-
meric sequences of human chromosomes. Based on the
size and specificity of these alpha-satellite probes we
selected human chromosome 1 (PUC 1.77) and 15
(D15Z1) [35].
Interphase FISH was performed according to pre-
viously described protocols on formalin-fixed paraffin-
embedded tissue slides [36]. Chromosome 1 (detected
by FITC, green) and chromosome 15 (detected by Cy3,
red) specific alpha satellite probes were labeled by using
standard nick translation procedure, hybridized and ana-
lyzed as previously described [37]. All slides were
embedded in Citifluor anti-fading solution containing
DAPI for visualization of DNA of the interphase nuclei.
Results
In vivo observation
All of the ten GCT samples were able to form solid vas-
cularized tumors when grafted to the CAM (Additional
file 1, Figure 1 and 2). No significant differences in the
growth rate were observed according to the primary
lesion. The percentage of tumors after 6 days of growth
in living embryos was 86.9% (60 of 69). The overall
death rate after grafting of the tumor tissue was 55% (69
of 125) and was significantly higher (P = 0.001, Fisher’s
exact test - Figure 3) than the death rate of the controls,
which was 19% (5 of 26).
24h after grafting of the suspension, a solid tumor
became apparent which then progressively further vas-
cularized without significantly increasing in size (Figure
1). With the typical yellow-brownish color and the
strong vascularization the tumors resembled the macro-
scopical aspect of GCT during surgery (Figure 2). The
overall mean estimated tumor volume was 12.3 mm
3
(4.3 - 35.6 mm
3, Additional file 1).
Histological and Immunohistochemical findings
The tumor samples cultured on the CAM contained
both (osteoclast-like) giant cell and mononuclear com-
ponents of GCT (Figure 4). The giant cells reacted for
CD68, which is expressed by both macrophages and
osteoclasts, and exhibited the typical immunophenotypic
profile of osteoclasts, being CD14- and CD51+ (Figure
5); giant cells in GCT exhibit a similar antigenic pheno-
type [38,39]. The mononuclear component contained
cells expressing CD68, CD14 and CD51. Giant cells
were numerous and widely scattered throughout the ori-
ginal tumors but fewer were noted in tumors cultured
on the CAM. Tumor giant cells frequently contained
more than five nuclei in the original tumors but were
smaller and contained fewer nuclei in the cultured sam-
ples. The tumors appear to grow on the membrane
rather than invade it, producing an implant-like rather
than infiltrative growth pattern. Vessels were recruited
from the CAM to vascularize the tumor. Ki-67 revealed
a very low proliferating fraction (less than 1%) of cells.
The tumors contained a background chronic inflamma-
tory cell infiltrate including lymphocytes and plasma
cells.
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For the discrimination between the human and chicken
cells, we performed interphase FISH using human
alpha-satellite probes specific to the heterochromatic
region of chromosome 1q12 and the (peri)centromeric
region of chromosomes 15. The two color labeling of
these two probes allows the identification of human
cells with FISH signals while chicken cells would be
stained with DAPI only. The use of a similar approach
to discriminate between human and mouse cells have
been shown by us earlier [34]. Despite the very strong
auto-fluorescence coming from extracellular matrix
material of the CAM, a clear recognition of the FISH
positive human cells were possible (Figure 6). FISH
image using two human centromeric probes (red, green)
Figure 1 In vivo observations of tumor growth. The tumor solute is seeded into the plastic ring on the CAM (0h). After 24 h a solid tumor
develops which gets further vascularized (24 to 144 h). The typical red/yellow-brownish color as well as areas of haemorrhage are visible. Upper
row magnification 10 ×, scale bar 1 mm; lower row magnification 20×, scale bar 500 μm.
Figure 2 Photographs of day 6 tumor. Another example of a
GCT grown on the CAM. Note the typical yellow-brownish color in
A and the strong vascularization of the tumor when the CAM is
turned upside down after fixation in B. Magnification 40 ×, scale bar
250 μm.
Figure 3 Survival of embryos after tumor grafting. The overall
death rate after grafting of the tumor tissue is siginficantly higher
than the death rate of the controls. P = 0.001, Fisher’s exact test.
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human and chicken centromeres. There was no signal
in the CAM nor in the remaining chicken erythrocytes
in the tumor nor in the vascular endothelium (Figure
6B). The giant cells were positive for FISH indicating
that they were of human origin.
Figure 4 Histology and Ki67 staining. Hematoxylin-eosin stain of a day 6 tumor (A and B) shows all cell components of a GCT and closely
resembles original tumor (C). Note the fewer giant cells (arrowheads) in A and B containing fewer nuclei compared to original tumor in C.
Note the very low proliferation activity (arrow) in the nuclear staining of MIB-1 in D. Magnification in A+C 20 × (scale bar 50 μm), B: 40 × (scale
bar 25 μm), D: 10 × (scale bar 100 μm).
Figure 5 Immunophenotypic profile of giant cells.T y p i c a l
immunophenotypic profile of osteoclasts, being CD51 + (A) and
CD14 - (B). Giant cells reacted for CD68 (C), which is expressed by
both macrophages and osteoclasts. Magnification 400 ×.
Figure 6 Fluorescence in situ hybridization.I n t e r p h a s eF I S H
overview using probes specific to human chromosome 1 (green)
and chromosome 15 (red) alpha-satellite sequences. Sections were
counterstained by DAPI (blue) showing nuclei of both human and
chicken cells. A: FISH signals were detected in human cells only,
chicken erythrocytes showed no signals (indicated by white arrows).
B: Human cells are well demarcated from CAM cells (dashed white
line) and attracted numerous blood vessels and erythrocytes (white
arrows).
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GCT is a locally aggressive primary tumor of bone that
commonly recurs and in some cases can be life threa-
tening [40]. Control of tumor growth and intervention
to reduce complications such as the development of pul-
monary metastases has hitherto not been possible [1,41].
The major problem in GCT research is the lack of ani-
mal models in which to study GCT growth and patho-
biology. Although mononuclear stromal cells can be
cultured from GCT, other significant cellular compo-
nents, notably macrophages and giant cells, do not
remain in culture after passaging [42,43]. Due to these
difficulties, very little is known on the pathobiology of
this particular tumor.
The CAM assay is an established in vivo model to
study angiogenesis [44]. It is characterized by several
advantages such as easy accessibility and relatively sim-
ple and cost effective experimental approach. Despite its
natural immunodeficient environment (for review see
[45]) the CAM assay is still rarely used for tumor graft-
ing. There are reports about the use of the CAM assay
as a reliable model to study tumors such as glioblastoma
[31], prostatic cancer [46], and melanoma [47], but com-
pared to murine models of tumor growth these are rela-
tively rare. Reports of the use of the CAM assay for
establishment of human bone and soft tissue tumors are
largely anecdotal [48,49].
Recently, we established the CAM assay for human
osteosarcoma cell lines and were able to show that the
MNNG-HOS, U2OS and SAOS cell lines consistently
developed vascularized tumors that simulated key fea-
tures of human osteosarcoma growth such as angiogen-
esis, necrosis and hemorrhage [33]. Compared to tumor
formation with osteosarcoma cell lines, where the num-
ber of successful implanted tumors was around 50%, the
number of tumors which resulted from suspensions of
GCTs seeded on the CAM was nearly 90% (60 of 69).
However, the overall embryonic mortality rate after
tumor grafting was 55% (69 of 125); this was higher
than in the previous osteosarcoma study where there
was an embryonic mortality rate of 38% (58 of 152)
[33]. The underlying reasons for this difference remain
speculative, but it is possible that the mortality rate may
correlate with tumor (graft) and host interactions; death
might be caused by tumor cell dissemination directly or
via secretion of specific factors causing blood coagula-
tion. Metabolic stress such as hypoxia and/or serum
deprivation [50], may occur in the tumors grafted to the
CAM and might induce tumor cells to secrete such
molecules.
One theory of GCT lung metastasis formation is that
tumor cells invade blood vessels and are disseminated
via the blood stream, finally implanting in the lungs.
Following implantation, GCTs become established by
inducing angiogenesis and further vascularization. The
cultured GCTs in our model appeared to grow on the
CAM and showed some morphological resemblance to
metastatic GCT lung nodules. Although the tumors
which grew on the CAM contained all the cellular com-
ponents of GCT, including stromal cells, macrophages
and multinucleated osteoclast-like giant cells, the latter
were generally less numerous than in the original
tumor, a morphological finding which has been noted in
GCT lung nodules [51]. Areas of necrosis and haemor-
rhage as well as extensive vascularization were present
in the tumors grown on the CAM, all features which
are typical for GCT. The Ki67 staining demonstrated a
very low proliferation rate, in contrast to the original
tumors. This might be due to the short time span (only
6 days) of tumor growth. Thus the model would appear
to simulate the early phase of tumor seeding, one of the
initial steps in the development of a metastasis or local
recurrence.
The FISH analysis provided evidence that the experi-
mental GCTs on the CAM are hybrid tumors composed
of human graft and chicken host (vasculature) cells.
Therefore the model might allow further studies clarify-
ing these crucial steps of angiogenesis and tumor inva-
sion and metastasis which are promising targets for new
drugs against solid tumors [52,53]. As an example it
m i g h tb ep o s s i b l et od e v e l o pn e wa n t i t u m o rd r u g sb y
simultaneous measuring of gene expression using Affy-
metrix chicken GeneChips and human GeneChips in
the tumor cells as well as in newly formed blood vessels,
as has been shown for pancreatic adenocarcinoma [32].
This model represents an excellent alternative to the
commonly used animal models. It is cost effective and
fulfills the recommendations of an ethically appreciable
use of live animals in cancer research [54]. The fact that
tumors were grown from a frozen cell suspension will
also favor exchange of material between different cen-
tres, an important point given the rarity of GCT.
The typical GCT can usually be locally controlled by
intralesional curettage or surgical removal. The treat-
ment options for complicated cases, such as GCT with
pulmonary metastases or GCT arising in a surgically
inaccessible site, are limited. To date only a few promis-
ing therapies have been developed for adjuvant use in
these cases. The few publications that exist on systemic
treatment of GCT have focused on inhibition of osteo-
clastic bone resorption with bisphosphonates or disrup-
tion of the RANK/RANKL pathway of osteoclast
formation with specific antibodies such as denosumab
[28,55]. The limitation of this treatment is that only
osteoclasts are inhibited, whereas the proliferating neo-
plastic stromal cells are mainly unaffected. Thus these
treatments might only have a short term effect. Use of
the CAM assay should permit the effect of therapeutic
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GCT to be studied in greater detail; this model should
also facilitate further molecular characterization of the
cellular components of this rare tumor.
Conclusions
A reliable protocol for grafting of human GCT onto the
chick chorio-allantoic membrane is established. This is
the first in vivo model for giant cell tumors of bone
which opens new perspectives to study this disease and
to test new therapeutical agents.
Additional material
Additional file 1: Table 1. Information on patients, anatomical
localization of tumor, mortality/growth rate and tumor size. M = male, F
= Female, prox = proximal, dist = distal, R = Recurrence, V mm
3 = mean
tumor volume calculated by V = 4/3*p*r
3 (r = 1/2 * square root of
diameter 1 * diameter 2), SD = standard deviation.
Additional file 2: Opening of the eggs. Video showing the process of
opening of the egg.
Additional file 3: Preparation of plastic rings. Video demonstrating
the preparation of the plastic rings.
Additional file 4: Placement of the plastic ring on the CAM. Video
showing the placement of the plastic ring on the CAM.
Additional file 5: Gentle laceration of the CAM surface. Video
showing the process of gentle laceration of the CAM surface.
Additional file 6: Grafting of the tumor cells. Video demonstrating the
technique of tumor cell grafting.
Additional file 7: Fixation and further processing of the tumor
tissue. Video demonstration the method of fixation and preparation of
the tissue for further processing.
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